Musings from The Power List: Ali Tavassoli
September 10, 2026
Ali Tavassoli explains how cyclic peptides and new discovery tools are opening up once-inaccessible biology
8 min read
False
Advertisement
2026
The Manufacturing Questions Facing Chinese Biotech
September 9, 2026
Lonza’s Wayne Wen discusses the growing maturity of China’s drug development and manufacturing ecosystem – and what companies need to compete internationally
5 min read
Musings from The Power List: Miguel Forte
September 8, 2026
Scientific progress alone isn't enough, says Miguel Forte, who argues that reimbursement and patient access will shape the next decade of cell and gene therapy
4 min read
CD19 CAR T Therapy Tested in Refractory Rheumatoid Arthritis
September 8, 2026
Disease activity fell in all six participants in a phase I trial, with three achieving sustained drug-free remission during follow-up
2 min read
Manufacturing Reality Behind Personalized Cancer Vaccines
September 7, 2026
As personalized cancer vaccines move closer to commercialization, manufacturers must rethink DNA production to deliver batch-for-one treatments with the required speed, consistency, and quality
3 min read
CAR T Before Surgery Improves Glioblastoma Control in Mice
September 7, 2026
Study finds that tumor resection creates a more immunosuppressive environment and that earlier CAR T cell treatment prolongs survival
2 min read
Musings from The Power List: Peng Lu
September 4, 2026
Peng Lu argues that small molecules remain indispensable as AI transforms drug development
2 min read
What Will Drug Development Look Like in 2036?
September 3, 2026
Members of The Medicine Maker’s 2026 Power List predict how AI, new modalities, integrated data, and shifting global markets will reshape the industry
7 min read
How Glycosylation Is Shaping Cancer Biomarker Discovery
September 2, 2026
Glycosylation could offer cancer researchers a new way to understand tumors, identify biomarkers, and develop more precise therapies
3 min read
China’s Biopharma Homecoming
September 1, 2026
Chinese biopharma leaders are returning from the West to build a more confident – and innovative – global industry, says Cyagen’s Lance Han
7 min read
